January 17th, 2024: Ratio Therapeutics Announces $50M Series B ...

Jan 17, 2024 · Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90Million Since 2021 Launch. BOSTON, January 17, 2024 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop …

CouponFollow Extension

$50
OFF

January 17th, 2024: Ratio Therapeutics Announces $50M Series B ...

1 week from now

ratiotx.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

1 week from now

BOSTON, Jan. 17, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class …

yahoo.com

$50
OFF

Ratio Therapeutics Raises $50M For Tumor-targeting …

1 week from now

Jan 17, 2024 · Ratio Therapeutics raises $50M for tumor-targeting radiopharmaceuticals. ... Ratio Therapeutics Inc. has secured the backing to move its first drug candidate into clinical trials by …

bizjournals.com

$50
OFF

Media - Ratio Therapeutics

1 week from now

Ratio Therapeutics raises $50M for tumor-targeting radiopharmaceuticals. Boston Business Journal | January 17th, 2024. The Boston company has secured the backing to move its first …

ratiotx.com

$50
OFF

Ratio Therapeutics Secures $50M Series B To Develop Cancer …

1 week from now

Jan 18, 2024 · Boston-based pharmaceutical company Ratio Therapeutics has announced the completion of a $50 million Series B financing round to advance its targeted radiotherapies for …

builtinboston.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

1 week from now

BOSTON, Jan. 17, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class …

biospace.com

$50
OFF

Ratio Therapeutics Secures Funds For Cancer Radiotherapies

1 week from now

Jan 18, 2024 · Ratio Therapeutics has secured $50m in a Series B financing round, a significant move aimed at advancing targeted radiotherapies for cancer treatment. The funding, which …

pharmaceutical-technology.com

$50
OFF

Ratio Therapeutics Raises $50M In Series B Financing

1 week from now

Jan 17, 2024 · Ratio Therapeutics Raises $50M in Series B Financing ... The platforms are designed to deliver radioactive isotopes to cancer cells without added toxicity, with Trillium …

precisionmedicineonline.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

1 week from now

Jan 17, 2024 · Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment ... altered to bind to any antigen-specific target, while …

prnewswire.com

$50
OFF

Ratio Therapeutics Raises $50M In Series B Financing - FinSMEs

1 week from now

By FinSMEs. -. January 19, 2024. Ratio Therapeutics, a Boston, MA-based pharmaceutical company, raised $50M in Series B funding. The round, which brought the total amount to …

finsmes.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

1 week from now

Jan 17, 2024 · Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90 Million Since 2021 Launch. BOSTON, MA, USA I January 17, 2024 I Ratio …

pipelinereview.com

$50000000
OFF

Series B - Ratio Therapeutics - 2024-01-17 - Crunchbase

1 week from now

Jan 17, 2024 · Ratio Therapeutics raised $50000000 on 2024-01-17 in Series B. Search Crunchbase. ... Law360 — Boston's Ratio Therapeutics Raises $50M Series B For R&D . ...

crunchbase.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

1 week from now

Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment PR Newswire BOSTON, Jan. 17, 2024 Boston-Based...

marketwatch.com

$745
OFF

Ratio Therapeutics Lands $745M Cancer Drug Development Deal …

1 week from now

2 hours ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 …

stocktitan.net

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

1 week from now

BOSTON, January 17, 2024-- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for …

vcaonline.com

FAQs about January 17th, 2024: Ratio Therapeutics Announces $50M Series B ... Coupon?

Will ratio Therapeutics move its first drug candidate into clinical trials?

Ratio Therapeutics Inc. has secured the backing to move its first drug candidate into clinical trials by the end of this year. The Boston company is developing radiopharmaceuticals for the treatment and monitoring of cancers. ...

Why are radiation treatments most effective for lymphoma?

Radiation therapy is extremely effective for lymphomas. The reason is lymphomas are radiosensitive. It means that they respond very well to even moderate doses of radiation. In radiation therapy, high-energy X-rays are used to destroy the abnormal cells that cause cancer. ...

How much money will ratio Therapeutics get from Novartis Pharma?

(RTTNews) - Ratio Therapeutics Inc. Monday announced partnership with Novartis Pharma AG, a unit of Novartis AG (NVS) to develop a radiotherapeutic candidate for cancer. As per the deal, Ratio will receive up to $745 million in upfront and potential milestone payments together. It is also entitled to get tiered royalty payments. ...

Who backed ratio's $50M Series B financing?

Ratio announced its $50M Series B financing Wednesday. Investors in this round of capital included Series A leads Duquesne Capital and Schusterman Family Investments, as well as new backers PagsGroup, Bristol Myers Squibb and the Center for Technology Licensing at Cornell University. ...

Does radiation treatment for other reasons cause cancer?

Radiation treatment for various medical reasons, including cancer, aims to benefit patients. While it's designed to target specific cells, there's a minimal risk of developing secondary cancers due to radiation exposure. Healthcare professionals take precautions to minimize risks, but long-term effects can vary based on factors like radiation dose and individual health. ...

Are treatments customized for people of different sizes of prostate cancer?

As with most malignant tumors, choosing the most appropriate treatment for prostate tumors will depend on the stage of the disease and not just the size of the tumor. Let us observe that prostate cancer is a disordered proliferation of cells originating in the prostate and that have the property of invading adjacent organs and tissues and of spreading throughout the body, establishing neoplastic implants at a distance. In this context, treatment proposals include surgery, radiotherapy, brachytherapy, or even simply active surveillance (consists of observing the evolution of the tumor, initially without specific therapy), which can even be associated in a treatment proposal, depending on the stage and aggressiveness of the tumor. ...